Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 11/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 10/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 5/20 | 0.39 |
| ▸ | CHUK | O15111 | 5/20 | 0.39 |
| ▸ | IKBKG | Q9Y6K9 | 5/20 | 0.39 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.38 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.38 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5618266 | 0.75 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1ALDH1A1HPGDACKR3 | |
| SCHEMBL279856 | 0.70 | L3MBTL3 (0.81) | L3MBTL3L3MBTL1ALDH1A1HPGDACKR3 | |
| SCHEMBL19396257 | 0.69 | L3MBTL3 (0.62) | L3MBTL3L3MBTL1ALDH1A1HPGDACKR3 | |
| SCHEMBL27688414 | 0.67 | L3MBTL3 (0.88) | L3MBTL3L3MBTL1ALDH1A1HPGDACKR3 | |
| SCHEMBL12265916 | 0.65 | L3MBTL3 (0.79) | L3MBTL3L3MBTL1ALDH1A1HPGDACKR3 | |
| SCHEMBL277178 | 0.65 | L3MBTL3 (0.79) | L3MBTL3L3MBTL1ALDH1A1HPGDACKR3 | |
| SCHEMBL12265877 | 0.65 | L3MBTL3 (0.74) | L3MBTL3L3MBTL1ALDH1A1HPGDACKR3 | |
| SCHEMBL12313389 | 0.65 | L3MBTL3 (0.74) | L3MBTL3L3MBTL1ALDH1A1HPGDACKR3 | |
| SCHEMBL14395488 | 0.65 | L3MBTL3 (0.78) | L3MBTL3L3MBTL1ALDH1A1HPGDACKR3 | |
| SCHEMBL2058050 | 0.64 | L3MBTL1 (0.57) | L3MBTL3L3MBTL1ALDH1A1HPGDACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186832-B2 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN INC. (US) | 2007-03-06 | — | — | US | claimed |
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | SUGEN, INC. | 2005-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009832-A1 | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors | MAP3K8, MAP3K2, MAP3K5 | L3MBTL3 4220/4885L3MBTL1 4405/4885ALDH1A1 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.